Search Within

Martin Stuart Tallman

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (44)
  2. Journal Article (41)
  3. Research Letter (3)
Groups
  1. Adult Leukemia (88)
  2. Center for Hematologic Malignancies (88)
  3. Department of Medicine (88)
  4. Department of Pathology and Laboratory Medicine (88)
  5. Hematologic Malignancies, Division of (88)
  6. GSK Faculty (63)

More Groups

People
  1. Ross Levine (54)
  2. Yanming Zhang (33)
  3. Maria Arcila (31)
  4. Mikhail Roshal (31)
  5. Christopher Famulare (27)
  6. Eytan Stein (27)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (3)
  4. 2022 (5)
  5. 2021 (8)
  6. 2020 (18)

More Years

Publications
  1. Blood (41)
  2. Blood Advances (8)
  3. Haematologica (5)
  4. American Journal of Hematology (3)
  5. Biology of Blood and Marrow Transplantation (3)
  6. Cancer Research (3)

More Publications

Publishers
  1. American Society of Hematology (49)
  2. Nature Publishing Group (8)
  3. American Association for Cancer Research (5)
  4. Ferrata Storti Foundation (5)
  5. Elsevier Inc. (3)
  6. Elsevier Ltd (3)

More Publishers

Results (88)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MSK-IMPACT Heme: Validation and clinical experience of a comprehensive molecular profiling platform for hematologic malignancies
    Meeting Abstract

    Ptashkin, R. N.; Benayed, R.; Ziegler, J.; Rema, A. B.; Sadowska, J.; Kiecka, I.; Ho, C.; Yao, J. J.; Moung, C.; Petrova-Drus, K.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
    Journal Article

    Taylor, J.; Haddadin, M.; Upadhyay, V. A.; Grussie, E.; Mehta-Shah, N.; Brunner, A. M.; Louissaintr, A. Jr; Lovitch, S. B.; Dogan, A.; Fathi, A. T.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia
    Journal Article

    Xiao, W.; Goldberg, A. D.; Famulare, C. A.; Devlin, S. M.; Nguyen, N. T.; Sim, S.; Kabel, C. C.; Patel, M. A.; McGovern, E. M.; Patel, A.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
    Journal Article

    Gu, Z.; Churchman, M. L.; Roberts, K. G.; Moore, I.; Zhou, X.; Nakitandwe, J.; Hagiwara, K.; Pelletier, S.; Gingras, S.; Berns, H.; more...
    Nature Genetics (2019)

    Fulltext@MSK | Save
  • A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease
    Journal Article

    Litzow, M. R.; Wang, X. V.; Carroll, M. P.; Karp, J. E.; Ketterling, R. P.; Zhang, Y.; Kaufmann, S. H.; Lazarus, H. M.; Luger, S. M.; Paietta, E. M.; more...
    American Journal of Hematology (2019)

    Fulltext@MSK | Save
  • Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation
    Journal Article

    Xiao, W.; Yabe, M.; Offin, M.; Khattar, P.; Baik, J.; Daley, R. J.; Pappacena, J. J.; Roshal, M.; Zhang, Y.; Tallman, M. S.; more...
    Blood Advances (2018)

    Fulltext@MSK | Save
  • Loss of plasmacytoid dendritic cell differentiation is highly predictive for persistent measurable residual disease and poor outcomes in acute myeloid leukemia
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Famulare, C.; Delvin, S.; Patel, M.; McGovern, E.; Patel, A.; Schulman, J.; Dunbar, A.; Epstein-Peterson, Z. D.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • PHF6 mutations are mutually exclusive to TP53 mutations, and define a distinct subgroup of secondary acute myeloid leukemia associated with a primitive stem/progenitor immunophenotype, absent complex karyotype and relatively better outcomes
    Meeting Abstract

    Xiao, W.; Goldberg, A. D.; Ball, B.; Famulare, C.; Pastore, F.; Tallman, M. S.; Zhang, Y.; Arcila, M. E.; Papaemmanuil, E.; Levine, R. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents
    Meeting Abstract

    Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to MRD-negative complete remissions
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Pratz, K. W.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save